Cadila Pharmaceuticals unveils aqueous Vitamin D injection
This breakthrough not only enhances the efficacy of treatment but also ensures a painless and easy administration process, marking a significant advancement in patient care.
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-02-28 07:10 GMT | Update On 2024-03-21 10:00 GMT
Advertisement
Ahmedabad: Cadila Pharmaceuticals has announced the launch of the world's first aqueous formulation of cholecalciferol for Vitamin D deficiency. This innovation demonstrates superior pharmacokinetics (PK) and pharmacodynamics (PD) compared to traditional oil-based cholecalciferol preparations available in the market.
Vitamin D deficiency is a major health concern globally, contributing significantly to the outcomes of various diseases.
"Cadila Pharmaceuticals' innovative aqueous cholecalciferol injection offers a unique solution with rapid correction of Vitamin D deficiency in short span of time. This breakthrough not only enhances the efficacy of treatment but also ensures a painless and easy administration process, marking a significant advancement in patient care," the Company stated.
The novel aqueous formulation demonstrates significant improvements in both pharmacokinetic and pharmacodynamics properties of the drug, outperforming conventional oil-based cholecalciferol preparations. Patients can benefit from a swift correction of Vitamin D deficiency in short span of time, addressing a critical need for expedited treatment outcomes in many major illnesses.
Further, the injection provides a painless experience for patients, promoting better compliance with treatment regimens.
The significance of Vitamin D extends well beyond bone health, influencing outcomes in various conditions such as Cardiovascular Disease, Diabetes Mellitus, and weakened immune systems. Vitamin D acts as an anti-hypertrophic agent, a stimulator of vascular smooth muscle cell proliferation, anti- fibrotic, antioxidant, anti-inflammatory, and an inhibitor of the Renin-Angiotensin-Aldosterone System (RAAS).
Dr. Rajiv I. Modi, Chairman and Managing Director, Cadila Pharmaceuticals, stated, "Our commitment to innovation and patient centric research to bridge the gap in areas of unmet medical need has driven the development of this ground-breaking aqueous cholecalciferol injection. We believe this advancement will redefine the landscape of Vitamin D deficiency treatment and ensure better treatment outcomes,"
Dr. Vijayesh Gupta , COO- BSBU, Cadila Pharmaceuticals, added, "With the launch of the world's first aqueous Vitamin D injection, Cadila Pharmaceuticals reaffirms its dedication to providing cutting-edge healthcare solutions. We anticipate this innovation will help clinicians to better design their treatment protocols for Vitamin D deficient patients and a large number of patients will benefit from the next generation, world’s first aqueous injectable Vitamin D."
Read also: Cadila Pharma inaugurates Greenfield API manufacturing plant at Dahej
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.